JNJ241227C155000
- 0.02
- 0.000.00%
Johnson & Johnson Newsroom
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
RxSight Cut to Hold at Stifel on Competition Concerns
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
After GE's Spinoff Success, What's Next for Honeywell, FedEx
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In?
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow's Drop: How Blue-chips Have Fared During Index's Peak Turned Worst-run in Decades
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Least Shorted S&P 500 Stocks in November
Dow on a Record Losing Streak: Should You Buy Its ETF?
Express News | J&J: Application to EMA for New Indication Approval for Imbruvica in Adults With Previously Untreated Mcl Eligible for Autologous Stem Cell Transplant
Express News | U.S. FDA Approves Celltrion's Steqeyma, Biosimilar to J&J's Stelara - Website
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $161
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC